{"pmid":32317203,"title":"Cardiovascular complications in COVID-19.","text":["Cardiovascular complications in COVID-19.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.","Am J Emerg Med","Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael","32317203"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19."],"journal":"Am J Emerg Med","authors":["Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317203","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.048","keywords":["acute myocardial infarction","covid-19","cardiovascular","dysrhythmia","heart failure","infectious disease","myocarditis","troponin"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087672623104,"score":8.518259,"similar":[{"pmid":32201335,"pmcid":"PMC7164881","title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.","J Am Coll Cardiol","Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A","32201335"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems."],"journal":"J Am Coll Cardiol","authors":["Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201335","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jacc.2020.03.031","keywords":["cardiovascular therapy","coronavirus","health system"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664639760403005440,"score":424.3175},{"pmid":32264791,"title":"Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System.","text":["Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System.","Angiotensin-converting enzyme (ACE2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system (RAS), facilitator of amino acid transport, and the SARS-CoV and SARS-CoV-2 receptor. ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue. ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for COVID-19, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease. Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes. The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications. Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS. Recombinant human ACE2 has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively. Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the RAS, together with implications for the COVID-19 pandemic and associated cardiovascular diseases.","Circ Res","Gheblawi, Mahmoud","Wang, Kaiming","Viveiros, Anissa","Nguyen, Quynh","Zhong, Jiu-Chang","Turner, Anthony J","Raizada, Mohan K","Grant, Maria B","Oudit, Gavin Y","32264791"],"abstract":["Angiotensin-converting enzyme (ACE2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system (RAS), facilitator of amino acid transport, and the SARS-CoV and SARS-CoV-2 receptor. ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue. ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for COVID-19, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease. Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes. The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications. Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS. Recombinant human ACE2 has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively. Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the RAS, together with implications for the COVID-19 pandemic and associated cardiovascular diseases."],"journal":"Circ Res","authors":["Gheblawi, Mahmoud","Wang, Kaiming","Viveiros, Anissa","Nguyen, Quynh","Zhong, Jiu-Chang","Turner, Anthony J","Raizada, Mohan K","Grant, Maria B","Oudit, Gavin Y"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32264791","week":"202015|Apr 06 - Apr 12","doi":"10.1161/CIRCRESAHA.120.317015","keywords":["angiotensin 1-7","angiotensin converting enzyme 2","covid-19","coronavirus","recombinant human ace2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664637636067721217,"score":407.07397},{"pmid":32282502,"title":"Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).","text":["Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).","A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.","J Cardiovasc Pharmacol","Dixon, Dave L","Van Tassell, Benjamin W","Vecchie, Alessandra","Bonaventura, Aldo","Talasaz, Azita","Kakavand, Hesam","D'Ascenzo, Fabrizio","Perciaccante, Antonio","Castagno, Davide","Ammirati, Enrico","Biondi-Zoccai, Giuseppe","Stevens, Michael","Abbate, Antonio","32282502"],"abstract":["A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions."],"journal":"J Cardiovasc Pharmacol","authors":["Dixon, Dave L","Van Tassell, Benjamin W","Vecchie, Alessandra","Bonaventura, Aldo","Talasaz, Azita","Kakavand, Hesam","D'Ascenzo, Fabrizio","Perciaccante, Antonio","Castagno, Davide","Ammirati, Enrico","Biondi-Zoccai, Giuseppe","Stevens, Michael","Abbate, Antonio"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282502","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FJC.0000000000000836","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["remdesivir","Chloroquine","Hydroxychloroquine"],"_version_":1664636703940280320,"score":406.51358},{"pmid":32311816,"title":"Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","text":["Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option. This article is protected by copyright. All rights reserved.","Catheter Cardiovasc Interv","Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D","32311816"],"abstract":["The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option. This article is protected by copyright. All rights reserved."],"journal":"Catheter Cardiovasc Interv","authors":["Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311816","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ccd.28946","keywords":["covid-19","stemi","acute myocardial infarction","emergency medical system","fibrinolysis","percutaneous coronary intervention"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664632501467873280,"score":383.85672},{"pmid":32330544,"title":"Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","text":["Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option.","J Am Coll Cardiol","Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D","32330544"],"abstract":["The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option."],"journal":"J Am Coll Cardiol","authors":["Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330544","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacc.2020.04.039","keywords":["covid-19","stemi","acute myocardial infarction","emergency medical system","fibrinolysis","percutaneous coronary intervention"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664996914860392450,"score":383.85672}]}